At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging Study to Determine the Effect of Mepolizumab on Exacerbation Rates in Subjects With Severe Uncontrolled Refractory Asthma
In Brief
A Phase 2 clinical trial evaluating Mepolizumab 750, Mepolizumab 250, and 2 other interventions for Asthma. Completed, enrolled 621 participants across 94 sites in 13 countries.
Detailed Summary
The purpose of this study is to show whether mepolizumab given every 4 weeks intravenously (i.v.) can reduce the frequency of asthma exacerbations in subjects with severe asthma despite receiving high doses of standard asthma medications. The study will look at different doses of mepolizumab in comparison to a placebo.
Study Details
Timeline
Interventions
Mepolizumab 750mg every four weeks by i.v.
Mepolizumab 250mg every four weeks by i.v.
Mepolizumab 75mg every four weeks by i.v.
Placebo saline every four weeks by i.v.